Viking Therapeutics Net Worth
Viking Therapeutics Net Worth Breakdown | VKTX |
Viking Therapeutics Net Worth Analysis
Viking Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Viking Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Viking Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Viking Therapeutics' net worth analysis. One common approach is to calculate Viking Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Viking Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Viking Therapeutics' net worth. This approach calculates the present value of Viking Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Viking Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Viking Therapeutics' net worth. This involves comparing Viking Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Viking Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Viking Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Viking Therapeutics' net worth research are outlined below:
| Viking Therapeutics generated a negative expected return over the last 90 days | |
| Viking Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (109.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Viking Therapeutics currently holds about 155.02 M in cash with (87.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.02. | |
| Roughly 74.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from fool.com: 1 Biotech Stock Down 52 percent That Could Soar by 233, According to Wall Street |
Viking Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Viking Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Viking Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of February 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Viking Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Viking Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Viking Therapeutics backward and forwards among themselves. Viking Therapeutics' institutional investor refers to the entity that pools money to purchase Viking Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Norges Bank | 2024-12-31 | 1.3 M | Pictet Asset Manangement Sa | 2024-12-31 | 1.2 M | Alliancebernstein L.p. | 2024-12-31 | 1.1 M | Susquehanna International Group, Llp | 2024-12-31 | 1 M | International Assets Investment Management, Llc | 2024-09-30 | 1 M | Perceptive Advisors Llc | 2024-12-31 | 995.9 K | Amvescap Plc. | 2024-12-31 | 872.8 K | Balyasny Asset Management Llc | 2024-12-31 | 860.4 K | Charles Schwab Investment Management Inc | 2024-12-31 | 728.7 K | Fmr Inc | 2024-12-31 | 16.7 M | Vanguard Group Inc | 2024-12-31 | 10.2 M |
Follow Viking Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.18 B.Market Cap |
|
Project Viking Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.12) | (0.13) | |
| Return On Capital Employed | (0.17) | (0.18) | |
| Return On Assets | (0.12) | (0.13) | |
| Return On Equity | (0.12) | (0.13) |
When accessing Viking Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Viking Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Viking Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Viking Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Viking Therapeutics. Check Viking Therapeutics' Beneish M Score to see the likelihood of Viking Therapeutics' management manipulating its earnings.
Evaluate Viking Therapeutics' management efficiency
Viking Therapeutics has return on total asset (ROA) of (0.1477) % which means that it has lost $0.1477 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.179) %, meaning that it created substantial loss on money invested by shareholders. Viking Therapeutics' management efficiency ratios could be used to measure how well Viking Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.13 in 2025. Return On Capital Employed is likely to drop to -0.18 in 2025. At this time, Viking Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 952.6 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 794.1 K in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 8.07 | 8.48 | |
| Tangible Book Value Per Share | 8.07 | 8.48 | |
| Enterprise Value Over EBITDA | (28.90) | (27.46) | |
| Price Book Value Ratio | 4.98 | 5.23 | |
| Enterprise Value Multiple | (28.90) | (27.46) | |
| Price Fair Value | 4.98 | 5.23 | |
| Enterprise Value | 342 M | 174.7 M |
Understanding the operational decisions made by Viking Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Viking Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Viking Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Viking Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Viking Therapeutics Corporate Filings
8K | 11th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 26th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
| 4th of February 2025 Other Reports | ViewVerify | |
F4 | 6th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Viking Therapeutics Earnings per Share Projection vs Actual
Viking Therapeutics Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Michael Morneau | Vice Administration | Profile | |
| Marianne Mancini | Chief Officer | Profile | |
| Geoffrey Barker | Senior Development | Profile |
Additional Tools for Viking Stock Analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.